Sarclisa
Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment
July 30, 2025Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma
Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …
Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
June 5, 2024Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …
Sanofi’s Sarclisa accepted for FDA priority review
May 29, 2024Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
Sanofi multiple myeloma drug approved for second indication by EC
April 19, 2021Sales and Marketing European Commission, Sanofi, Sarclisa, pharma, pharma news
The European Commission (EC) has approved a second indication of Sanofi’s Sarclisa drug for the treatment of adult patients with …
New Sanofi Sarclisa treatment for multiple myeloma approved by FDA
April 1, 2021FDA, FDA Approval, Sanofi, Sarclisa, multiple myeloma
Sanofi’s Sarclisa drug has been approved by the FDA in combination with carfilzomib and dexamethasone (Kd) for the treatment of …
NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma
October 16, 2020Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma
Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …
Sanofi’s Sarclisa combo approved in Europe for relapsed/refractory multiple myeloma
June 2, 2020Manufacturing and Production, Sales and Marketing Europe, Sanofi, Sarclisa, pharma
Sanofi has scored a new approval from the European Commission for the use of its CD38 inhibitor Sarclisa (isatuximab) in …
Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma
Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
